- Trials with a EudraCT protocol (54)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
54 result(s) found for: Impression management.
Displaying page 2 of 3.
EudraCT Number: 2013-003219-22 | Sponsor Protocol Number: LMS/SF/UH/0018 | Start Date*: 2014-01-27 | |||||||||||
Sponsor Name:Hertfordshire Partnership University NHS Foundation Trust [...] | |||||||||||||
Full Title: A randomised controlled feasibility trial comparing clinical and cost effectiveness of cognitive behavioural therapy (CBT) and selective serotonin reuptake inhibitors (SSRI) and their combination i... | |||||||||||||
Medical condition: Obsessive Compulsive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005010-43 | Sponsor Protocol Number: COL MIG-202 | Start Date*: 2009-06-22 | |||||||||||
Sponsor Name:CoLucid Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Double Blind Randomized Placebo-Controlled Parallel Group Dose-Ranging Study of Oral COL-144 in the Acute Treatment of Migraine | |||||||||||||
Medical condition: Migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) BE (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003456-70 | Sponsor Protocol Number: CTH-302 | Start Date*: 2017-03-22 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 compared to s.c. Apomorphine in Levodopa Responsive Subjects with Parkinson's Disease Complicated ... | |||||||||||||
Medical condition: Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations ("OFF episodes") | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003342-15 | Sponsor Protocol Number: F1D-MC-HGMT | Start Date*: 2007-12-05 |
Sponsor Name:Eli Lilly and Company Limited | ||
Full Title: A Randomized, Open-Label Study Comparing the Effectiveness of Olanzapine Pamoate Depot with Haloperidol Decanoate in the Treatment of Schizophrenia | ||
Medical condition: Schizophrenia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) FR (Completed) GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001047-31 | Sponsor Protocol Number: M12-821 | Start Date*: 2014-05-14 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain | |||||||||||||
Medical condition: Moderate to Severe Endometriosis Associated Pain | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) AT (Completed) IT (Completed) ES (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004592-36 | Sponsor Protocol Number: RD.03.SPR.29097 | Start Date*: 2012-04-12 | |||||||||||
Sponsor Name:Galderma R&D | |||||||||||||
Full Title: Subjects’ satisfaction on pan facial aesthetic enhancement after treatment with Azzalure® and the Restylane® range | |||||||||||||
Medical condition: Facial volume loss and dynamic wrinkles of the upper third of the face | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001634-18 | Sponsor Protocol Number: M602011072 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:Merz Pharmaceuticals GmbH | |||||||||||||||||||||||
Full Title: A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lo... | |||||||||||||||||||||||
Medical condition: Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Trial now transitioned) LV (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020471-23 | Sponsor Protocol Number: OTR3001 | Start Date*: 2011-05-31 | |||||||||||
Sponsor Name:Purdue Pharma L.P. | |||||||||||||
Full Title: An Open-label, Multicentre Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children from Ages 6 to 16 Years Old, Inclusive, with Moderate... | |||||||||||||
Medical condition: Opioid tolerant paediatric patients with moderate to severe malignant and/or nonmalignant pain requiring opioid therapy. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) SK (Completed) DE (Completed) FI (Completed) ES (Completed) EE (Completed) BE (Completed) GR (Prematurely Ended) PL (Completed) SE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005117-72 | Sponsor Protocol Number: AG120-C-005 | Start Date*: 2017-04-24 | ||||||||||||||||
Sponsor Name:Agios Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation | ||||||||||||||||||
Medical condition: Nonresectable or Metastatic Cholangiocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001891-73 | Sponsor Protocol Number: SD-809-C-20 | Start Date*: 2014-11-12 |
Sponsor Name:Auspex Pharmaceuticals, Inc. | ||
Full Title: AN OPEN-LABEL, LONG-TERM SAFETY STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA | ||
Medical condition: Tardive Dyskinesia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) PL (Completed) SK (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-021096-85 | Sponsor Protocol Number: FT-1301-032-SP | Start Date*: 2011-04-12 | |||||||||||
Sponsor Name:Nycomed | |||||||||||||
Full Title: A dose titrated clinical trial with a placebo-controlled, double-blind, randomised, cross-over phase to demonstrate the efficacy of 400 μg Intranasal fentanyl (INFS) dose strength, and to evaluate ... | |||||||||||||
Medical condition: Breakthrough Pain (BTP) in adult cancer patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019930-28 | Sponsor Protocol Number: 31116 | Start Date*: 2011-03-09 | |||||||||||
Sponsor Name:Accare | |||||||||||||
Full Title: The effectiveness of Parent-Child Interaction Therapy versus methylphenidate in preschool children with ADHD and disruptive behavior problems with insufficient improvement through Parent Management... | |||||||||||||
Medical condition: ADHD ODD | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001802-30 | Sponsor Protocol Number: TMP-3001-2020-30 | Start Date*: 2021-10-28 |
Sponsor Name:Fraunhofer Institut für Translationale Medizin und Pharmakologie (ITMP) | ||
Full Title: Efficacy of belimumab to improve subclinical cardiovascular abnormalities using imaging endpoints with cardiac magnetic resonance in patients with systemic lupus erythematosus (BeCarma) | ||
Medical condition: Efficacy of belimumab to improve subclinical cardiovascular abnormalities using imaging endpoints with cardiac magnetic resonance in patients with systemic lupus erythematosus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001509-21 | Sponsor Protocol Number: B7981037 | Start Date*: 2020-12-08 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE SAFETY OF RITLECITINIB (PF 06651600) IN ADULT PARTICIPANTS WITH ALOPECIA AREATA | |||||||||||||
Medical condition: Alopecia areata | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002534-16 | Sponsor Protocol Number: FSJD-INNOVA-2020 | Start Date*: 2021-10-15 | |||||||||||
Sponsor Name:Fundació Sant Joan de Déu | |||||||||||||
Full Title: 12-month randomized, double-blind, placebo-controlled, pharmacological clinical trial to evaluate the effectiveness, cost-utility and neurobiological effects of low-dose Naltrexone in patients with... | |||||||||||||
Medical condition: Fibromyalgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002113-19 | Sponsor Protocol Number: 42756493CAN2002 | Start Date*: 2019-10-31 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations | |||||||||||||
Medical condition: Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) DE (Trial now transitioned) ES (Ongoing) BE (Completed) IT (Completed) Outside EU/EEA SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005173-28 | Sponsor Protocol Number: BLU-263-1201 | Start Date*: 2021-09-06 | |||||||||||
Sponsor Name:Blueprint Medicines Corporation | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | |||||||||||||
Medical condition: Indolent Systemic Mastocytosis (ISM) and monoclonal Mast Cell Activation Syndrome (mMCAS) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005760-42 | Sponsor Protocol Number: MBGS205 | Start Date*: 2016-05-25 | |||||||||||
Sponsor Name:Mereo BioPharma 2 Limited | |||||||||||||
Full Title: A Phase IIb multicentre, double-blind, dose-ranging, randomised, placebo-controlled study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism | |||||||||||||
Medical condition: Hypogonadotropic hypogonadism (HH) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020841-29 | Sponsor Protocol Number: ADAPT | Start Date*: 2011-07-07 | ||||||||||||||||
Sponsor Name:King`s College London [...] | ||||||||||||||||||
Full Title: The role of anti-IgE (omalizumab) in the management of severe recalcitrant paediatric atopic eczema | ||||||||||||||||||
Medical condition: Severe eczema in children | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004752-16 | Sponsor Protocol Number: BP40283 | Start Date*: 2021-07-30 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF RO6889450 (RALMITARONT) IN PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AND NEGATIVE SYMPTOMS | ||||||||||||||||||
Medical condition: Schizophrenia or schizoaffective disorder | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) HR (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
